15289-s-bos

8 129 | Novel protein biomarker predictors of CAD in FH Table 8.3 | Associations between protein biomarkers and CAD severity in FH patients. LRG1 ITIH3 C4B C1QB CD14 HRG Disease severity score rho p -0.078 0.636 0.140 0.395 -0.028 0.868 -0.117 0.479 -0.180 0.274 -0.060 0.717 CAD severity score rho p -0.094 0.569 0.122 0.460 -0.025 0.879 -0.137 0.405 -0.181 0.269 -0.084 0.610 SIS score rho p -0.107 0.519 0.125 0.447 -0.066 0.692 -0.172 0.296 -0.189 0.248 -0.100 0.544 CAD extent 05 rho p -0.146 0.377 0.037 0.821 0.014 0.934 -0.146 0.377 -0.125 0.447 -0.026 0.874 CAD extent 04 rho p -0.144 0.381 0.038 0.819 0.015 0.928 -0.143 0.384 -0.125 0.447 -0.026 0.877 Univariate analysis of the association between peptides and CAD severity., LRG1 :Leucine-rich alpha-2- glycoprotein, ITIH3 :Inter-alpha-trypsin inhibitor heavy chain H3, C4B :Complement C4-B, C1QB :Complement C1q subcomponent subunit B, CD14 :Monocyte differentiation antigen, HRG :Histidine-rich glycoprotein, Rho: Spearmans’s rho rank-order correlation coefficient, p: Significance for the H0 test that rho=0. A logistic regression analysis comparing these three proteins and the Framingham score indicates that for C4B and C1QB, the Framingham score is superior as an indicator of arterial calcification. With HRG we found a significant interaction with the Framingham score so that together the two measures provide enhanced discrimination between asymptomatic FH patients and those with calcification (HRG: p=0.011, Framingham: p=0.007 and interaction: p=0.014, AUC=0.858). Figure 8.2 | Proportion of patients within each disease severity group with any of the indicator proteins detected.